Curative effect of desloratadine citrate disodium and fexofenadine in refractory urticaria
10.3969/j.issn.1005-1678.2017.03.077
- VernacularTitle:枸地氯雷他定联合非索非那定治疗难治性荨麻疹患者的疗效
- Author:
Xuefeng FU
;
Meiyan WANG
;
Na ZHANG
- Keywords:
desloratadine citrate disodium;
fexofenadine;
refractory urticaria;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(3):249-251
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of desloratadine citrate disodium and fexofenadine in the treatment of refractory urticaria . Methods 100 patients with refractory urticaria were randomly divided into observation group and control group according to the digital table method, with 50 cases in each group.The control group were treated with desloratadine citrate disodium, and the observation group were treated with fexofenadine on the basis of control group.The efficacy, immunity function ( CD3 +, CD4 +, CD4 +/CD8 +) , the changes of inflammatory factors [ procalcitonin ( PCT) , C-reactive protein ( CRP) ] and the quality of life were compared between the two groups.The adverse reaction rate in two groups was recorded in two groups.Results The total efficacy in observation group (88.0%) was significantly higher than that in control group (72.0%)(P<0.05).The indicators of immunity function in observation group were significantly higher than those in control group(P<0.05).The inflammatory factors in observation group were significantly lower than those in control group ( P<0.05 ) .The sleep and exercise quality rate of the observation group were significantly higher than those in control group(86.0% vs.68.0%,84.0% vs.66.0%,P<0.05).Conclusion The combination of desloratadine citrate disodium and fexofenadine in the treatment of refractory urticaria has a good effect, can effectively improve the immune function, reduce the secretion of inflammatory factors, thus effectively relieve the clinical symptoms, improve their quality of life, and has high security.
